The antimicrobial susceptibility of Mycobacterium chelonae isolated from corneal ulcer

Current Eye Research

Volumn 16, Issue 10, 1997, Pages 1056-1060

  Hu, Fung Rong ^a   Chang, Shan Chwen ^a   Luh, Kwen Tay ^a   Hung, Por T ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antibiotics; In vitro susceptibility; Keratitis; Mycobacterium chelonae

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; ETHAMBUTOL; GENTAMICIN; IMIPENEM; ISONIAZID; MACROLIDE; MINOCYCLINE; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; QUINOLONE; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TOBRAMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CORNEA ULCER; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM CHELONEI; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CORNEA; CORNEAL ULCER; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL;

EID: 0030751468     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.16.10.1056.9023     Document Type: Article

References (30)

1. Turner, L. and Stinson, I. (1965) Mycobacterium fortuitum as a cause of corneal ulcer. Am. J. Ophthalmol. 60, 329-331.
2. Kubica, G. P., Baess, I., Gordon, R. E., Jenkins, P. A., Kwapinski, J. B. G., McDurmont, C., Pattyn, S. R., Saito, H., Silcox, V., Stanford, J. L., Takeya, K. and Tsukamura, M. (1972) A co-operative numerical analysis of rapidly growing mycobacteria. J. Gen. Microbiol. 73, 55-70.
3. Meisler, D. M., Friedlander, M. H. and Okumoto, M. (1982) Mycobacterium chelonae keratitis. Am. J. Ophthalmol. 94, 398-401.
4. Dugel, P. U., Holland, G. N., Brown, H. H., Pettit, T. H., Hofbauer, J. D., Simons, K. B., Ullman, H., Bath, P. E. and Foos, R. Y. (1988) Mycobacterium fortuitum keratitis. Am. J. Ophthalmol. 105, 661-669.
5. Wallace, R. J., Jr., Bedsole, G., Sumter, G., Sanders, C. V., Steele, L. C., Brown, B. A., Smith, J. and Graham, D. R. (1990) Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 34, 65-70.
6. Ichiyama, S. and Tsukamura, M. (1987) Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. Chest, 92, 1110-1112.
7. Wallace, R. J., Jr., Swenson, J. M., Silcox, V. A. and Bullen, M. G. (1985) Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonae on the basis of in vitro susceptibility. J. Infect. Dis. 152, 500-514.
8. Wallace, R. J., Jr., Brown, B. A. and Onyi, G. O. (1991) Susceptibility of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clovulanic acid. Antimicrob. Agents Chemother. 35, 773-775.
9. Swenson, J. M., Wallace, R. J., Silcox, V. A. and Thornsberry, C. (1985) Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28, 807-811..
10. Khardori, N., Nguyen, H., Rosenbaum, B., Rolston, K. and Bodey, G. P. (1994) In vitro susceptibilities of rapid growing mycobacteria to newer antimicrobial agents. Antimicrob. Agents Chemother. 38, 134-137.
11. Silcox, V. A., Good, R. C. and Floyd, M. M. (1981) Identification of clinically significant Mycobacterium fortuitum complex isolates. J. Clin. Microbiol. 14, 686-691 .
12. National Committee for Clinical Laboratory Standards (1990) Methods for Dilution: Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd ed. National Committee for Clinical Laboratory Standards, Villanova, PA, USA.
13. Krogstad, D. J. and Moellering, R. C., Jr. (1986) Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 2nd ed. (Ed. Lorian, V.). Pp. 537-595. Williams & Wilkins, Baltimore, MD.
14. Sanders, W. E., Hartwig, E. C., Schneider, N. J., Cacciatore, R. and Valdez, H. (1977) Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents. Antimicrob. Agents Chemother. 12, 295-297.
15. Grassi, C. and Peona, V. (1995) New drugs for tuberculosis. Eur. Respir. J. 8, 714s-718s.
16. Bullington, R. H., Lanier, J. D. and Font, R. L. (1992) Nontuberculous mycobacterial keratitis: report of two cases and review of the literature. Arch. Ophthalmol. 110, 519-524.
17. Insler, M. S., Helm, C. J. and George, W. J. (1987) Topical vs. systemic gentamicin penetration into the human cornea and aqueous humor. Arch. Ophthalmol. 105, 922-924.
18. Davison, C. R., Tuft, S. J. and Dart, J. K. G. (1991) Conjunctival necrosis after administration of topical fortified aminoglycosides. Am. J. Ophthalmol. 11, 690-693.
19. Swenson, J. M., Thornsberry, C. and Silcox, V. A. (1982) Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22, 186-192.
20. Yew, W. W., Piddock, L. J. V., Li, M. S. K., Lyon, D., Chan, C. Y. and Cheng, A. F. B. (1994) In vitro activity of quinolones and macrolides against mycobacteria. J. Antimicrob. Chemother. 34, 343-351.
21. O'Brien, T. P., Sawusch, M. R., Dick, J. D. and Gottsch, J. D. (1988) Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch. Ophthalmal. 106, 1444-1446.
22. Lin, R., Holland, G. N., Helm, C. J., Elias, S. J., Berlin, O. G. W. and Bruckner, D. A. (1994) Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis is an animal model. Am. J. Ophthalmol. 117, 657-662.
23. Barry, A. L., Jones, R. N. and Thornsberry, C. (1988) In vitro activities of azithromycin (CP62993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32, 752-754.
24. Bahal, N. and Nahata, M. C. (1992) The new macrolide antibiotics: azithromycin, clarithromycin, airithromycin, and roxithromycin. Ann. Pharmacother. 6, 46-53.
25. Brown, B. A., Wallace, R. J., Jr., Onyi, G. O., De Rosas, V. and Wallace, R. J. (1992) Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob. Agents Chemother. 36, 180-184.
26. Gross, R. H., Holland, G. N., Elias, S. J. and Tuz, R. (1995) Corneal pharmacokinetics of topical clarithromycin. Invest. Ophthalmol Vis. Sci. 36, 965-968.
27. Helm, C. J., Holland, G. N., Lin, R., Berlin, O. G. W. and Bruckner, D. A. (1993) Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model. Am. J. Ophthalmol. 116, 700-707.
28. Watt, B., Edwards, J. R., Rayner, A., Grindey, A. J. and Harris, G. (1992) In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber. Lung Dis. 73, 134-136.
29. Yew, W. W., Kwan, S. Y. L., Wong, P. C. and Lee, J. (1990) Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle, 71, 131-133.
30. Matoba, A. Y., Lee, B. L., Robinson, N. M., Penland, R. and Osato, M. S. (1993) Combination drug testing of Mycobacterium chelonae. Invest. Ophthalmol. Vis. Sci. 34, 2786-2789.